Drug Interactions between abiraterone and Allegra
This report displays the potential drug interactions for the following 2 drugs:
- abiraterone
- Allegra (fexofenadine)
Interactions between your drugs
No interactions were found between abiraterone and Allegra. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
abiraterone
A total of 401 drugs are known to interact with abiraterone.
- Abiraterone is in the drug class miscellaneous antineoplastics.
- Abiraterone is used to treat Prostate Cancer.
Allegra
A total of 110 drugs are known to interact with Allegra.
- Allegra is in the drug class antihistamines.
- Allegra is used to treat the following conditions:
Drug and food interactions
fexofenadine food
Applies to: Allegra (fexofenadine)
GENERALLY AVOID: Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine. The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate. In a five-way crossover study with 10 healthy volunteers, 1/4-strength grapefruit juice, grapefruit juice, orange juice and apple juice (300 mL with drug administration and 150 mL every 1/2 hour for up to 3 hours, total volume 1.2 L) reduced the mean area under the plasma concentration-time curve (AUC) of a 120 mg dose of fexofenadine by 23%, 67%, 72% and 77%, respectively, compared to water. Mean peak plasma concentration (Cmax) was similarly affected. The clinical significance of these changes is unknown. However, results from studies using histamine-induced skin wheals and flares found that the size of wheal and flare was significantly larger when fexofenadine was administered with either grapefruit or orange juices compared to water.
MANAGEMENT: To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water. In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.
References
- Bailey DG, Dresser GK, Munoz C, Freemar DJ, Kim RB (2001) "Reduction of fexofenadine bioavailability by fruit juices." Clin Pharmacol Ther, 69, PI-82
- Dresser GK, Bailey DG, Leake BF, et al. (2002) "Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine." Clin Pharmacol Ther, 71, p. 11-20
abiraterone food
Applies to: abiraterone
ADJUST DOSING INTERVAL: Food may significantly increase the oral bioavailability of some formulations of abiraterone acetate. Compared to administration in the fasted state, abiraterone peak plasma concentration (Cmax) and systemic exposure (AUC) were approximately 7- and 5-fold higher, respectively, when a single dose of abiraterone acetate was administered with a low-fat meal (7% fat; 300 calories) and approximately 17- and 10-fold higher, respectively, when it was administered with a high-fat meal (57% fat; 825 calories). Given the normal variation in the content and composition of meals, taking abiraterone acetate with meals has the potential to result in increased and highly variable exposures. The safety of these increased exposures during multiple dosing has not been assessed. However, the abiraterone acetate 125 mg tablet, commonly marketed as Yonsa, was found to have an approximately 6.5-fold higher Cmax and 4.4-fold higher AUC when a single dose of 500 mg (4 tablets) was administered with a high-fat meal (56% - 60% fat, 900 - 1000 calories) compared to overnight fasting in healthy volunteers. These differences were not considered clinically significant for this formulation.
MANAGEMENT: Some formulations of abiraterone acetate must be taken on an empty stomach. No food should be consumed for at least two hours before and one hour after the abiraterone acetate dose. However, the abiraterone acetate 125 mg tablet, commonly marketed as Yonsa, can be taken with or without food. The manufacturer's product labeling should be consulted for specific guidance.
References
- (2011) "Product Information. Zytiga (abiraterone)." Centocor Inc
- (2023) "Product Information. Akeega (abiraterone-niraparib)." Janssen Biotech, Inc.
- (2023) "Product Information. Akeega (abiraterone-niraparib)." Janssen Inc
- (2021) "Product Information. Zytiga (abiraterone)." Janssen Biotech, Inc.
- (2022) "Product Information. Yonsa (abiraterone)." Sun Pharmaceutical Industries
- (2023) "Product Information. Apo-Abiraterone (abiraterone)." Apotex Inc
- (2021) "Product Information. Zytiga (abiraterone)." Janssen-Cilag Pty Ltd
- (2023) "Product Information. Abiraterone (abiraterone)." Wockhardt UK Ltd
- (2023) "Product Information. Yonsa Mpred (abiraterone-methylprednisolone)." Sun Pharma ANZ Pty Ltd
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.